Doxorubicin-induced cardiomyopathy

New England Journal of Medicine

Volumn 339, Issue 13, 1998, Pages 900-905

  Singal, Pawan K ^a,b   Iliskovic, Natasha ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; DOXORUBICIN; METOPROLOL; RAZOXANE;

ANGIOCARDIOGRAPHY; CARDIOMYOPATHY; DIAGNOSTIC APPROACH ROUTE; DRUG CHOICE; DRUG EFFECT; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEART FUNCTION TEST; HEART MUSCLE BIOPSY; HEART PROTECTION; HUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW;

ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; DOXORUBICIN; HUMANS; RISK FACTORS;

EID: 0032563825     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199809243391307     Document Type: Review

References (54)

1. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 1973;32:302-14.
2. Harrison DT, Sanders LA. Pericarditis in a case of early daunorubicin cardiomyopathy. Ann Intern Med 1976;85:339-41.
3. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults: a review of 110 cases. Am J Med 1977;62:200-8.
4. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.
5. Bristow MR. Anthracycline cardiotoxicity. In: Bristow MR, ed. Drug-induced heart disease. New York: Elsevier, 1980:191-215.
6. Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979;63:827-34.
7. Minow RA, Benjamin RS, Lee EF, Gottlieb JA. Adriamycin cardiomyopathy - risk factors. Cancer 1977;39:1397-402.
8. Gilladoga AC, Manuel C, Tan CT, Wollner N, Sternberg SS, Murphy ML. The cardiotoxicity of Adriamycin and daunomycin in children. Cancer 1976;37:Suppl:1070-8.
9. Billingham ME, Bristow MR, Glatstein E, Mason JW, Masek MA, Daniels JR. Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1977;1:17-23.
10. Pihkala J, Saarinen UM, Lundstrom U, et al. Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 1996;32A:97-103.
11. Benjamin RS. Clinical pharmacology of Adriamycin (NSC-123127). Cancer Chemother Rep 1975;6:183-5.
12. Kim YD, Lees DE, Lake CR, et al. Hyperthermia potentiates doxorubicin-related cardiotoxic effects. JAMA 1979;241:1816-7.
13. Mancuso L, Marchi S, Canonico A. Dynamic left ventricular outflow obstruction and myocardial infarction following doxorubicin administration in a woman affected by unsuspected hypertrophic cardiomyopathy. Cancer Treat Rep 1985;69:241-4.
14. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978;62:873-9.
15. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266:1672-7.
16. Singal PK, Deally CMR, Weinberg LE. Subcellular effects of Adriamycin in the heart: a concise review. J Mol Cell Cardiol 1987;19:817-28.
17. Sinha BK, Katki AG, Batist G, Cowan KH, Myers CE. Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. Biochem Pharmacol 1987;36:793-6.
18. Rosen GM, Halpern HJ. Spin trapping biologically generated free radicals: correlating formation with cellular injury. Methods Enzymol 1990; 18:611-21.
19. Singal PK, Siveski-Iliskovic N, Hill M, Thomas TP, Li T. Combination therapy with probucol prevents Adriamycin-induced cardiomyopathy. J Mol Cell Cardiol 1995;27:1055-63.
20. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 1980;65:128-35.
21. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997;11:931-6.
22. Lewis AB, Crouse VL, Evans W, Takahashi M, Siegel SE. Recovery of left ventricular function following discontinuation of anthracycline chemotherapy in children. Pediatrics 1981;68:67-72.
23. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995;24:352-61.
24. Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996;53:461-70.
25. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 1983;106:1048-56.
26. Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979;300:278-83.
27. Ritchie JL, Singer JW, Thorning D, Sorensen SG, Hamilton GW. Anthracycline cardiotoxicity: clinical and pathologic outcomes assessed by radionuclide ejection fraction. Cancer 1980;46:1109-16.
28. Piver MS, Marchetti DL, Parthasarathy KL, Bakshi S, Reese P. Doxorubicin hydrochloride (Adriamycin) cardiotoxicity evaluated by sequential radionuclide angiocardiography. Cancer 1985;56:76-80.
29. Bhattacharya S, Lahiri A. Clinical role of indium-111 antimyosin imaging. Eur J Nucl Med 1991;18:889-95.
30. Sisson JC, Wieland DM, Sherman P, Mangner TJ, Tobes MC, Jacques S Jr. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 1987;28:1620-4.
31. Wakasugi S, Inoue M, Tazawa S. Assessment of adrenergic neuron function altered with progression of heart failure. J Nucl Med 1995;36: 2069-74.
32. Takano H, Ozawa H, Kobayashi I, et al. Atrophic nerve fibers in regions of reduced MIBG uptake in doxorubicin cardiomyopathy. J Nucl Med 1995;36:2060-1.
33. Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and noninvasive methods of assessing Adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 1978;62:857-64.
34. Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 1981;102:709-18.
35. Bristow MR. Toxic cardiomyopathy due to doxorubicin. Hosp Pract (Off Ed) 1982;17:101-8.
36. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992;19:670-86.
37. Schlumberger M, Brugieres L, Gicquel C, Travagli J-P, Droz J-P, Parmentier C. 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 1991;67:2997-3000.
38. Price FV, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). Gynecol Oncol 1993;51:383-9.
39. Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen: a prospective randomized evaluation. Cancer 1990;65:870-3.
40. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133-9.
41. Speyer JL, Green MD, Dubin N, et al. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. Am J Med 1985;78:555-63.
42. Bielack SS, Erttmann R, Winkler K, Landbeck G. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol 1989;25:873-82.
43. Treat J, Greenspan A, Forst D, et al. Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst 1990;82:1706-10.
44. Green D, Bensely D, Schein P. Preclinical evaluation of WR-151327: an orally active chemotherapy protector. Cancer Res 1994;54:738-41.
45. Seifert CF, Nesser ME, Thompson DF. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 1994;28:1063-72. [Erratum, Ann Pharmacother 1994;28:1413.]
46. Williams GA, Johnson JR, Burke G. FDA oncology drugs advisory committee review of Zinecard (dexrazoxane, ADR-529, ICRF-187). Rockville, Md.: Center for Drug Evaluation and Research, 1992:1-13.
47. Curran CF, Narang PK, Reynolds RD. Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity. Cancer Treat Rev 1991;18:241-52.
48. Hjalmarson A, Waagstein F. The role of β-blockers in the treatment of cardiomyopathy and ischaemic heart failure. Drugs 1994;47:Suppl 4:31-9.
49. Shaddy RE, Olsen SL, Bristow MR, et al. Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J 1995;129:197-9.
50. Luthy A, Furrer M, Waser M, et al. Orthotopic heart transplantation: an efficient treatment in a young boy with doxorubicin-induced cardiomyopathy. J Heart Lung Transplant 1992;11:815-6.
51. Arico M, Nespoli L, Pedroni E, Bonetti F, Vigano M, Burgio GR. Heart transplantation in a child with doxorubicin-induced cardiomyopathy. N Engl J Med 1988;319:1353.
52. Iliskovic N, Singal PK. Lipid-lowering: an important factor in preventing Adriamycin-induced heart failure. Am J Pathol 1997;150:727-34.
53. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucol protects against Adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995;91:10-5.
54. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 1992;89:942-9.